GlassScriptPhysician profile
Bernadette Ramos
NPI 1326715913
$6,498.25
in general payments reported to CMS, 2019-2025
28 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,129 · 2023: $2,114 · 2024: $1,908 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,349 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,349.19 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,825.55 | 2022-2024 | Breztri, Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $893.82 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $837.03 | 2022-2025 | |
| Novo Nordisk INC | $654.72 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Intra-Sana Laboratories | $511.73 | 2024-2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.97 | 2023-2025 | Jardiance |
| Amgen INC. | $275.83 | 2024-2025 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $162.50 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.74 | 2022-2024 | Trulance, Xifaxan |
| Viiv Healthcare Company | $125.00 | 2025 | Apretude |
| Scilex Pharmaceuticals INC. | $118.12 | 2024-2025 | |
| Vifor Pharma, INC. | $88.67 | 2022-2023 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $71.50 | 2023 | Rexulti, Nuedexta |
| Ardelyx, INC. | $62.79 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $61.63 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.02 | 2023-2025 | |
| Exact Sciences Corporation | $46.65 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $30.58 | 2022-2025 | Verquvo |
| Teva Pharmaceuticals USA, INC. | $29.69 | 2023 | Austedo |
| Corcept Therapeutics | $20.80 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $18.64 | 2025 | |
| Neurocrine Biosciences, INC. | $17.15 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.47 | 2024 | |
| Lundbeck LLC | $16.37 | 2023 | Rexulti |
| Smith+Nephew, INC. | $14.52 | 2023 | Collagenase Santyl |
| Nestle Healthcare Nutrition INC. | $12.67 | 2022 | |
| Horizon Therapeutics Plc | $12.45 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.